Fresenius Medical Care’s Value-Based Care Revenue Surges 34%

Forward-Looking Analysis

Fresenius Medical Care (FMS) is expected to report strong second-quarter 2026 results, building on the momentum established in Q3 2025. In that quarter, FMS reported adjusted earnings per share (EPS) of 64 cents, beating Zacks Consensus Estimates by 8.47%, with the bottom line improving 35.8% year over year. Revenues reached $5.71 billion, surpassing estimates by 4.3%, representing a 2.6% year-over-year increase and an 8.3% rise at constant currency. Management noted that divestitures as part of the portfolio optimization plan negatively impacted revenue by EUR 50 million in Q3 2025, with a full-year 2024 negative impact of 100 basis points anticipated.

Segmental performance highlights the strength of the new operating model implemented in 2024. The Care Delivery segment saw revenues decline 2% year-over-year but gain 3.6% at constant currency and 6% organically. In the U.S., revenues fell 1% but grew 6% organically, supported by reimbursement rate increases, favorable payor mix, and reduced implicit price concessions. International sales declined 5% reported but grew 4% organically, driven by a 1.2% same-market treatment growth. The Care Enablement segment revenues remained flat year-over-year but gained 5% at constant currency and organically, driven by volume growth and positive pricing.

A key growth driver is the Value-Based Care (VBC) segment, where revenues surged 34% year-over-year, 42% at constant currency, and 42% organically. This growth was fueled by a significantly higher number of member months due to contract expansion. For Q2 2026, CEO Helen Giza confirmed the company delivered continued operational and financial progress in the first quarter, with organic revenue growth, improved profitability, and adjusted EPS growth. Operating income growth aligned with planned phasing, and Care Delivery posted strong operating income growth. Excluding positive TDAPA effects, underlying Care Delivery operating income improved by 6%. The company remains on track to maintain Group operating income at a consistent high level while overcoming regulatory headwinds, confirming its 2026 outlook.

Historical Performance Review

Fresenius Medical delivered robust results in the first quarter of 2026, generating $4.61 billion in revenue with a gross profit of $1.18 billion. Net income stood at $164.76 million, translating to an EPS of $0.43. These figures underscore the company's ability to drive organic growth and improve profitability despite regulatory challenges, setting a solid foundation for the upcoming Q2 report.

Additional News

Fresenius Medical Care continues to advance its "FME Reignite" strategy through innovation and strategic partnerships. In July 2026, the company announced BEACON-US, a study generating real-world evidence supporting high-volume hemodiafiltration for U.S. dialysis patients. Additionally, FMS introduced TherapyWise™ analytics for kidney replacement therapy in July 2026, enhancing clinical decision-making. The rollout of the innovative 5008X CAREsystem has accelerated, with the device now available in approximately 100 clinics and over 100,000 treatments performed. The company also highlighted Interwell Health's strong quality scores and shared savings in the CMS Value-Based Kidney Care Model in June 2026. These developments reflect a focus on high-volume hemodiafiltration as a benchmark for survival evidence and improved patient outcomes.

Summary & Outlook

Fresenius Medical Care demonstrates solid financial health, evidenced by consistent organic revenue growth and improved profitability in early 2026. Key growth catalysts include the successful rollout of the 5008X CAREsystem, expansion in Value-Based Care, and the introduction of TherapyWise™ analytics. While regulatory headwinds persist, the company's confirmed 2026 outlook and strong Q1 performance suggest a bullish trajectory. The focus on operational efficiency and innovative therapies positions FMS to sustain margin expansion and shareholder value creation in the coming quarters.